CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Phase 2

Withdrawn

Conditions: Metastatic Melanoma

Interventions: Drug: Abraxane

First Posted Date: 2013-08-30

Last Posted Date: 2014-02-04

Lead Sponsor: Celgene Corporation

Registration Number: NCT01933061

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Phase 1

Completed

Conditions: Hematologic Neoplasms

Interventions: Drug: Enasidenib

First Posted Date: 2013-08-05

Last Posted Date: 2024-10-22

Lead Sponsor: Celgene

Target Recruit Count: 345

Registration Number: NCT01915498

Locations: 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 21 locations

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Phase 1

Terminated

Conditions: Hodgkin Lymphoma
Chronic Myelomonocytic Leukemia
Acute Myeloid Leukemia
Multiple Myeloma
Non-Hodgkin Lymphoma
Myelodysplastic Syndromes

Interventions: Drug: Oral azacitidine

First Posted Date: 2013-07-25

Last Posted Date: 2015-07-28

Lead Sponsor: Celgene Corporation

Target Recruit Count: 2

Registration Number: NCT01908387

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
National Cancer Center Hospital, Tokyo, Japan
🇯🇵
The Cancer Institute Hospital of JFCR, Tokyo, Japan

CC-223 and Ketoconazole Drug-Drug Interaction Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ketoconazole
Drug: CC-223

First Posted Date: 2013-07-11

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 14

Registration Number: NCT01896323

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Phase 2

Completed

Conditions: Triple-negative Metastatic Breast Cancer
Metastatic Breast Cancer
HER2- Negative Breast Cancer
Recurrent Breast Cancer
Cancer of the Breast
Progesterone Receptor- Negative Breast Cancer
Stage IV Breast Cancer
Triple-negative Breast Cancer
Breast Tumor
Breast Cancer

Interventions: Drug: nab-Paclitaxel
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2013-06-19

Last Posted Date: 2019-02-21

Lead Sponsor: Celgene

Target Recruit Count: 191

Registration Number: NCT01881230

Locations: 🇺🇸
South Carolina Oncology Associates, Columbia, South Carolina, United States
🇺🇸
UT Physicians General Medicine, Houston, Texas, United States
🇧🇷
Centro de Oncologia Da Bahia, Salvador, Bahia, Brazil

and more 135 locations

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

Phase 1

Completed

Conditions: Clinical Pharmacology, Healthy Volunteer Study

Interventions: Drug: Pomalidomide

First Posted Date: 2013-04-19

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT01835561

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute
Myelodysplastic Syndromes

Interventions: Drug: CC-486

First Posted Date: 2013-04-19

Last Posted Date: 2018-11-20

Lead Sponsor: Celgene

Target Recruit Count: 31

Registration Number: NCT01835587

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center., New York, New York, United States
🇺🇸
MD Anderson Cancer Center The University of Texas, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 2 locations

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: VTX-2337
Drug: Cisplatin
Drug: Carboplatin
Drug: Placebo
Drug: 5-fluorouracil

First Posted Date: 2013-04-19

Last Posted Date: 2019-10-29

Lead Sponsor: Celgene

Target Recruit Count: 195

Registration Number: NCT01836029

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 50 locations

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

Phase 3

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Oral Azacitidine
Drug: Placebo

First Posted Date: 2012-12-31

Last Posted Date: 2024-08-28

Lead Sponsor: Celgene

Target Recruit Count: 472

Registration Number: NCT01757535

Locations: 🇺🇸
Swedish Cancer Inst, Seattle, Washington, United States
🇺🇸
Local Institution - 039, San Antonio, Texas, United States
🇺🇸
Arizona Oncology Associates, P.C., Phoenix, Arizona, United States

and more 220 locations

A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Revlimid

First Posted Date: 2012-12-19

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 100

Registration Number: NCT01752075

Locations: 🇨🇳
NTUH, Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy